DYADIC INTERNATIONAL INC (DYAI)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

0.44 on 9 Oct 2026

0 buys3 sales at will0 planned sales

Key numbers

Fiscal year 2025, ended 31 Dec 2025, as filed

Revenue

$3.09M

Net income

$7.36M

Free cash flow

$5.70M

Operating margin

-232.8%

Net margin

-238.3%

Return on equity

-597.6%

Return on capital

-461.1%

Revenue growth, 1 yr

-11.6%

Revenue growth, 5 yr

14.0% a year

Revenue and profit

Fiscal years, as filed with the SEC · point at a year for the detail

Full statements →

RevenueNet incomeLoss

Latest insider transactions

From Form 4, most recent first

All of them →

Date	Insider	Type	Value	Of own stake
24 Jul 2026	Francisco Trust under agreement dated February 28, 1996 10% owner	Sold at will	$3.17K	0.1%
23 Jul 2026	Francisco Trust under agreement dated February 28, 1996 10% owner	Sold at will	$71.30K	1.6%
22 Jul 2026	Francisco Trust under agreement dated February 28, 1996 10% owner	Sold at will	$50.48K	1.1%
1 Aug 2025	Hazelton Joseph P President and COO	Bought	$24.70K	20.1%
7 Jan 2025	Francisco Trust under agreement dated February 28, 1996 10% owner	Sold at will	$30.22K	0.4%
6 Jan 2025	Francisco Trust under agreement dated February 28, 1996 10% owner	Sold at will	$38.46K	0.6%

Clue Score

How it works

28out of 100

Profitability 25

Financial strength 9

Growth 38

Insiders 45

Strongest on insiders (45), weakest on financial strength (9). A score of the business, not of the price.

What insiders did

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$124.96K

3 sales

Planned sales

under a 10b5-1 plan

Every insider, every trade →

Profile

Sector: Health care
Industry: Biological Products, (No Diagnostic Substances)
Country: United States
SEC filings: EDGAR →